The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This study is a phase II randomized multicenter study. Patients will be enrolled at time of
diagnosis and will receive one or two cycles of induction chemotherapy. Patients, without
indication of intensification by allogeneic stem cell transplantation and/or without HLA
(Human Leukocyte Antigen)-compatible donor, who attain a CR after one or two cycles of
induction chemotherapy, will be eligible for the study Clofarabine / Intermediate-Dose
Cytarabine (CLARA)versus High-Dose Cytarabine (HDAC)and will be randomized between 3 courses
of CLARA chemotherapy and 3 courses of HDAC chemotherapy as consolidation.
We will compare efficacy and toxicity among the two arms.